What is Mellitus?
Mellitus is a private biotechnology company focused on the development and commercialization of an innovative in vitro diagnostic assay for measuring Glycated CD59 (GCD59). This biomarker holds potential for providing insights into glycemic control, aiding in the screening, diagnosis, and monitoring of diabetes, as well as stratifying the risk of complications and supporting pharmaceutical development. The company's lead product candidate targets Gestational Diabetes Mellitus (GDM), leveraging patented technology originating from research at Harvard Medical School.
How much funding has Mellitus raised?
Mellitus has raised a total of $3.1M across 2 funding rounds:
Debt
$992K
Debt
$2.1M
Debt (2016): $992K, investors not publicly disclosed
Debt (2017): $2.1M, investors not publicly disclosed
What's next for Mellitus?
The substantial enterprise-level funding and strategic investment indicate a pivotal phase for Mellitus. This capital infusion is expected to accelerate the commercialization of its GCD59 diagnostic assay, particularly for GDM. Future developments will likely involve scaling production, expanding clinical validation, and potentially seeking regulatory approvals to bring this diagnostic tool to market. The company's focus on a critical unmet need in diabetes management positions it for significant growth and impact within the healthcare sector.
See full Mellitus company page
